Managing Treatment-Resistant Depression: Road to Novel Therapeutics - Softcover

Über die Autorinnen und Autoren

João L. de Quevedo, MD, Ph.D., obtained his Medical Degree and completed residency training in Psychiatry, a fellowship in Psychopharmacology, and a Ph.D. in Biological Sciences (Biochemistry), all from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil. He is the John S. Dunn Distinguished Professor at the Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston). He also serves as Professor, Vice-Chair for Faculty Development and Outreach, Executive Director of the Center for Interventional Psychiatry, Chief of the Division of Interventional Psychiatry, Director of the Treatment-Resistant Depression Program, and Program Director of the Interventional Psychiatry Fellowship. Dr. Joao L. de Quevedo is an Associate Editor for Molecular Psychiatry, a Springer Nature journal.

Research profiles:

ResearcherID: E-5491-2013

Scopus Author ID: 56971689500

https://orcid.org/0000-0003-3114-6611

Dr. Patricio Riva-Posse, MD is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. After completing his training in Neurology and in Psychiatry, he has focused his clinical and research work in the field of treatment resistant mood disorders. He is the Director of the Treatment Resistant Depression Clinic, and Director of Neuromodulation Services. He conducts research in invasive and non-invasive neuromodulation as well as novel pharmacological approaches. He is an investigator in NIH-funded project studying subcallosal cingulate deep brain stimulation. Born in Argentina, he earned his Medical Doctor degree from the Universidad de Buenos Aires.

Dr. William V. Bobo, M.D., M.P.H., is Professor of Psychiatry at the Mayo Clinic Alix School of Medicine and Chair, Department of Psychiatry & Psychology at Mayo Florida, where he also serves as the Medical Director for Leadership Development. His clinical and research interests are focused on the treatment of patients with refractory mood disorders and on examining and predicting the clinical effects ― both beneficial and harmful--of medications used to treat people with severe mood disorders. He lives with his wife in Jacksonville, Florida.

Von der hinteren Coverseite

Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD.